| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e61817cecb3f8cb08195d35d1398f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d14846f96e774b3cbd1cf41d947ee5e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41a639aa11b9b2f8063a3e6b8b22b557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a3b81bba468d2e9b84d4447662044c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_700ff9a01db2075489cb7ed87392dc28 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-644 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 |
| filingDate |
2008-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07992648abf7f4c76a2166ff6bdb5d2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f21daf020d4009a8c29ffdcc775fb0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0e007ef8a51036dd809988ac814201c |
| publicationDate |
2008-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008092644-A2 |
| titleOfInvention |
Fviii-independent fix-mutant proteins for hemophilia a treatment |
| abstract |
The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors. Therefore these FIX mutants are alternatives as bypassing agents for treatment of FVIII inhibitor patients. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344608-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2390323-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10125357-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413598-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2767587-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3623470-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2149603-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010012451-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11517631-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2009275391-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10842885-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3241899-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3623470-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2390323-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10883097-B2 |
| priorityDate |
2007-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |